Filtered By:
Drug: Losartan

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 204 results found since Jan 2013.

Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Authors: Mancusi C, Gerdts E, de Simone G, Midtbø H, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB Abstract We tested the prognostic impact of a marker of arterial stiffness, pulse pressure/stroke volume index (PP/SVi) in patients with hypertension and left ventricular (LV) hypertrophy. We used data from 866 patients randomized to losartan or atenolol-based antihypertensive treatment, over a median of 4.8 years, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. The association of PP/SVi with outcomes was tested in Cox regression analyses and reported as hazard ratio (...
Source: Blood Pressure - October 7, 2016 Category: Hematology Tags: Blood Press Source Type: research

The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations.
CONCLUSION: Losartan therapy in haploinsufficient Marfan patients increases biventricular end diastolic volume and stroke volume, furthermore, losartan also appears to ameliorate biventricular filling properties. PMID: 27704402 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - October 3, 2016 Category: Cardiology Authors: den Hartog AW, Franken R, van den Berg MP, Zwinderman AH, Timmermans J, Scholte AJ, de Waard V, Spijkerboer AM, Pals G, Mulder BJ, Groenink M Tags: Neth Heart J Source Type: research

Safety and Efficacy of Losartan/Hydrochlorothiazide Combination in Elderly Patients with Morning Hypertension: Mappy Study
Background: Cardiovascular events, such as stroke and myocardial infarction, occur most frequently in the morning. Morning hypertension is characteristic feature of hypertension in the elderly, and is attributed to hypertensive organ damage and cardiovascular events. However, treatment of morning hypertension has not been established, especially in the elderly patients. The aim of this study was to compare the safety and effectiveness between an an angiotensin II receptor blocker (ARB) / hydrochlorothiazide (HCTZ) combination therapy and high-dose ARB therapy in the elderly (75 years or more) and younger (less than 75 years) patients.
Source: Journal of Cardiac Failure - August 24, 2016 Category: Cardiology Authors: Hiroki Uchiwa, Hisashi Kai, Yoshiko Iwamoto, Takahiro Anegawa, Kenji Fukuda, Tsutomu Imaizumi, Yoshihiro Fukumoto Source Type: research

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
ConclusionsThe combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - August 11, 2016 Category: Endocrinology Authors: N. G. C. Sande, J. A. N. Dorresteijn, F. L. J. Visseren, J. P. Dwyer, P. J. Blankestijn, Y. Graaf, H. L. J. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy
Conclusion: Abnormal PTFV1, a marker of left atrial abnormality, was strongly associated with incident stroke in hypertensive patients, independent of in-treatment SBP and other predictors of incident stroke. This association, in the absence of detectable atrial fibrillation, suggests that an underlying atrial cardiopathy may cause left atrial thrombus formation and a subsequent stroke without intervening clinically recognized atrial fibrillation.
Source: Journal of Hypertension - August 5, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Heart Source Type: research

Pattern of antihypertensive therapy among diabetic hyperten- sive patients in zewditu memorial hospital, addis ababa.
CONCLUSION: The pattern of antihypertensive drug therapy in our patients was consistent with the current treatment guidelines. However, the majority of diabetic-hypertensive patients did not reach target blood pressure. PMID: 27476227 [PubMed - in process]
Source: Ethiopian Medical Journal - August 3, 2016 Category: African Health Tags: Ethiop Med J Source Type: research

Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy
Conclusions The combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy varies considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: Nicolette G.C. van der Sande, Jannick A.N. Dorresteijn, Frank. L.J. Visseren, Jamie P. Dwyer, Peter J. Blankestijn, Yolanda van der Graaf, Hiddo L. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Fimasartan: A New Angiotensin Receptor Blocker
Abstract Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one derivative of losartan with the imidazole ring replaced, which enables higher potency and longer duration than losartan. Fecal elimination and biliary excretion are the predominant elimination pathways of fimasartan and the urinary excretion was found to be less than 3 % 24 h after administration. Fimasartan is primarily catabolized by cytochrome P450 isoform 3A and no significant drug interaction was observed when used in combination with hydrochlorothia...
Source: Drugs - June 6, 2016 Category: Drugs & Pharmacology Source Type: research

Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity
In conclusion, in patients of African ethnicity, treatment initiated with ACE inhibitor or angiotensin II receptor blocker monotherapy was associated with adverse cardiovascular outcomes. We found no evidence of different efficacy of antihypertensive drugs in South Asians, but there is a need for trials with morbidity and mortality outcomes. Screening for cardiovascular risk at a younger age, treating hypertension at lower thresholds, and new delivery models to find, treat and follow hypertensives in the community may help reduce the excess cardiovascular mortality in these high-risk groups.
Source: Internal and Emergency Medicine - March 29, 2016 Category: Emergency Medicine Source Type: research

Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9
Publication date: 2 March 2016 Source:Journal of Ethnopharmacology, Volume 180 Author(s): Rong Wang, Hai Zhang, Yujie Wang, Xiaoyan Yu, Yongfang Yuan Losartan (LST) is a common chemical drug used to treat high blood pressure and reduce the risk of stroke in certain people with heart disease. Danshen, prepared from the dried root and rhizome of Salvia miltiorrhiza Bunge, has been widely used for prevention and treatment of various cardiovascular and cerebrovascular diseases. There are more than 35 formulations containing Danshen indexed in the 2010 Chinese Pharmacopoeia, which are often combined with LST to treat car...
Source: Journal of Ethnopharmacology - February 6, 2016 Category: Drugs & Pharmacology Source Type: research

Prehypertensive treatment with losartan, however not amlodipine, leads to long‑term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke‑prone rats.
Authors: Zhang L, He D, Lin J Abstract The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke‑prone (SHRSP) rats against the risk of stroke. SHRSP rats were administered losartan, amlodipine or the vehicle for 6 weeks. There were no significant differences in systolic blood pressure (SBP) in rats treated with losartan or amlodipine, however, following drug withdrawal, rats treated with losartan maintained reduced SBP for a longer time compared with rats treated with amlodipine. In addition, rats treated with losartan exhibited thinner vascular walls...
Source: Molecular Medicine Reports - December 11, 2015 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy
Background: Assessment of antihypertensive treatment is normally based on the mean value of a number of blood pressure (BP) measurements. However, it is uncertain whether high in-treatment visit-to-visit BP variability may be harmful in hypertensive patients with left ventricular hypertrophy (LVH). Methods: In 8505 patients randomized to losartan vs. atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6–24months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 2...
Source: Journal of Hypertension - November 12, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: BP measurement Source Type: research

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness
Increased arterial stiffness is a common characteristic of humans with Williams-Beuren syndrome and mouse models of elastin insufficiency. Arterial stiffness is associated with multiple negative cardiovascular outcomes, including myocardial infarction, stroke, and sudden death. Therefore, identifying therapeutic interventions that improve arterial stiffness in response to changes in elastin levels is of vital importance. The goal of this study was to determine the effect of chronic pharmacologic therapy with different classes of antihypertensive medications on arterial stiffness in elastin insufficiency. Elastin-insufficie...
Source: AJP: Heart and Circulatory Physiology - September 1, 2015 Category: Cardiology Authors: Halabi, C. M., Broekelmann, T. J., Knutsen, R. H., Ye, L., Mecham, R. P., Kozel, B. A. Tags: INTEGRATIVE CARDIOVASCULAR PHYSIOLOGY AND PATHOPHYSIOLOGY Source Type: research